TABLE 6.

GMTs of bactericidal and opsonophagocytic activitiesa

StudyGroupBactericidal activityOpsonophagocytic activity
No. of responders above detection limit/total no. of subjectsGMT (95% CI)No. of responders above detection limit/total no. of subjectsGMT (95% CI)
United States
    PostprimaryDTPa + HBV + OPV + Hib*16/2620.89 (13.16-33.16)b33/5722.24 (12.911-38.310)b
DTPa-HBV-IPV/Hib11/237.53 (5.51-10.29)25/607.42 (5.078-10.842)
    PostboosterDTPa + Hib*32/33122.73 (72.27-208.44)33/33286.11 (112.41-728.12)
DTPa/Hib33/33148.27 (102.59-214.31)33/33245.1 (124.13-483.94)
Germany B
    PostprimaryDTPa-HBV + Hib29/4016.00 (11.84-21.63)b
DTPa-HBV/Hib19/397.58 (6.03-9.54)
    PreboosterDTPa-HBV + Hib9/396.35 (4.97-8.11)
DTPa-HBV/Hib4/394.61 (4.09-5.20)
    Postboosterdtpa-HBV + PRP35/4076.11 (45.87-126.28)
dtpa-HBV/PRP37/40130.24 (84.78-200.06)
Myanmar
    PostprimaryDTPw-HBV/Hib2.523/2538.9 (23.4-64.4)
DTPw-HBV/Hib25/2551.3 (34.6-76.0)
    PostboosterDTPw-HBV/Hib2.525/25216.8 (126.7-370.9)
DTPw-HBV/Hib24/25235.6 (138.5-400.6)
Germany A
    PostprimaryDTPa + Hib41/5621.4 (13.84-33.68)b
DTPa/Hib14/723.74 (3.15-4.45)
    PostboosterDTPa + Hib34/34462.2 (266.7-801.1)b
DTPa/Hib64/64215.9 (158.3-294.6)
  • a Blood samples were collected 1 month after the three-dose primary series and before and 4 to 6 weeks after the booster dose. CI, confidence interval; dtpa, experimental DTPa vaccine with reduced antigen content; Hib2.5, Hib vaccine containing 2.5 μg PRP conjugated to TT; OPV, oral poliomyelitis vaccine; *, OmniHIB.

  • b P < 0.05 for comparisons between groups receiving the mixed and separately administered vaccines at the specified time points (ANOVA for postbooster time points and the postprimary time point for the Myanmar study and Kruskal-Wallis test for all other postprimary and prebooster time points).